Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 12/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25343196 | 0.89 | TRPM8 (0.45) | IDO1TRPM8TRPV1PKMGPR119 | |
| SCHEMBL31024667 | 0.89 | TRPM8 (0.45) | IDO1TRPM8TRPV1PKMGPR119 | |
| SCHEMBL20096619 | 0.85 | IDO1 (0.56) | IDO1PKMGPR119 | |
| SCHEMBL1691354 | 0.85 | TRPM8 (0.59) | IDO1TRPM8TRPV1GPR119KDM1A | |
| SCHEMBL25342059 | 0.83 | IDO1 (0.47) | IDO1TRPM8TRPV1PKMGPR119 | |
| SCHEMBL18148459 | 0.81 | IDO1 (0.47) | IDO1TRPM8TRPV1PKMGPR119 | |
| SCHEMBL25339942 | 0.80 | IDO1 (0.45) | IDO1TRPM8TRPV1PKMGPR119 | |
| SCHEMBL25340767 | 0.80 | IDO1 (0.45) | IDO1TRPM8TRPV1PKMGPR119 | |
| SCHEMBL12482111 | 0.80 | IDO1 (0.58) | IDO1TRPM8TRPV1GPR119 | |
| SCHEMBL20096859 | 0.80 | TRPM8 (0.49) | IDO1TRPM8PKMGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | VALO HEALTH, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | Valo Health, LLC | 2019-03-21 | — | — | US | disclosed |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | VALO HEALTH, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | VALO EARLY DISCOVERY, INC. | 2018-05-10 | — | — | US | disclosed |
| WO-2018075959-A1 | METHODS USING HDAC11 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345672-B2 | Methods using HDAC11 inhibitors | HDAC11, HDAC1, HDAC10 | IDO1 2827/4885TRPM8 4783/4885TRPV1 4793/4885 |
| US-20180127386-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | IDO1 2827/4885TRPM8 4783/4885TRPV1 4793/4885 |
| US-20190084945-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | IDO1 2827/4885TRPM8 4783/4885TRPV1 4793/4885 |
| US-20190084946-A1 | METHODS USING HDAC11 INHIBITORS | HDAC11, HDAC1, HDAC10 | IDO1 2827/4885TRPM8 4783/4885TRPV1 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.